Blog
New assay identifies sufferers with altered p300/CBP acetylation in castration-resistant prostate most cancers
25
Jul
Jul
A brand new analysis paper was printed in Oncotarget’s Quantity 14 on July 20, 2023, entitled, “Improvement of a multiplex assay to evaluate activated p300/CBP in circulating prostate tumor cells.” Decreased SIRT2 deacetylation and elevated p300 acetylation exercise results in a concerted mechanism of hyperacetylation at particular histone lysine websites (H3K9, H3K14, and H3K18) in […]